home / stock / apto / apto news

APTO News and Press, Aptose Biosciences Inc. From 10/23/23

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APTO
Market: NASDAQ
Website: aptose.com
Menu
APTO APTO Quote APTO Short APTO News APTO Articles APTO Message Board
Get APTO Alerts

News, Short Squeeze, Breakout and More Instantly...
APTO - Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...
APTO - Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

SAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

APTO - Aptose to Present at the Cantor Global Healthcare Conference

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic maligna...

APTO - Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignanc...
APTO - Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

APTO - Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript

2023-08-10 23:01:11 ET Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Conference Call Aug 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer ...

APTO - Aptose Biosciences GAAP EPS of -$2.27 misses by $0.34

2023-08-10 16:58:16 ET Aptose Biosciences press release ( NASDAQ: APTO ): Q2 GAAP EPS of -$2.27 misses by $0.34 . Research and development expenses increased by $4.7 million to $19.4 million for the six-month period ended June 30, 2023. Total cash and cash equivale...
APTO - Aptose Reports Results for the Second Quarter 2023

─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ─ ─ CRc 43% in Patients with Wildtype FLT3 ─ ─ CRc 67% in P...

APTO - Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ende...

APTO - Aptose Biosciences meets Nasdaq compliance requirement

2023-06-27 05:56:29 ET Clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, Aptose Biosciences ( NASDAQ: APTO ) receives Nasdaq notice that it meets compliance with the Nasdaq’s minimum...
Previous 10 Next 10